Telomir Pharmaceuticals, Inc. Common Stock - TELO

SEC Filings Our TELO Tweets

About Gravity Analytica

Recent News

09.09.2025 - Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
08.28.2025 - Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
08.07.2025 - Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
07.24.2025 - Telomir Pharmaceuticals Reports Telomir-1’s Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer’s and Parkinson’s
07.18.2025 - Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin
06.18.2025 - Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria – an Ultra-Rare Genetic Disorder that Causes Rapid Aging
06.11.2025 - Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson’s Disease Model
06.05.2025 - Telomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Telomir Pharmaceuticals, Inc. Common Stock - TELO

About Gravity Analytica

Recent News

Recent Filings